Today, precision diagnostics remain expensive, time-consuming, and difficult to scale, which makes early detection inaccessible to many. As a result, countless diseases go unnoticed until it is too late for effective intervention.
At Molsentech, we are redefining the future of precision diagnostics.
By harnessing ultra-precise microfluidic biochips, we dramatically reduce the cost and complexity of diagnostics. This breakthrough enables true early detection and timely treatment, particularly for chronic and progressive diseases such as cancer and dementia. When diagnosed at an early stage, patients can receive simpler and more affordable therapies, avoiding the need for complex late-stage treatments such as immunotherapy, gene therapy, or cell therapy, which may cost over 100 times more.
Our vision goes beyond individual care. By deploying rapid and scalable testing infrastructure at airports, seaports, and other key entry points, we are building a global disease surveillance network. This allows infected individuals to be identified before community transmission occurs. Through targeted isolation and zone-based containment, we can significantly reduce transmission rates (R₀) and provide valuable lead time for vaccine development and coordinated public health response. In doing so, we can help prevent localized outbreaks from escalating into full-scale pandemics.
We believe in the universal value of life, and we are committed to the principle that equitable and effective healthcare should be a global standard, not a luxury.
At Molsentech, we are developing the next generation of precision diagnostics: Sharper. Smarter. Quicker.
Smart diagnostics made simple — ultra-sensitive, lightning-fast, scalable, and effortless to use.
+886-2-2783-5173
support@molsentech.com
© 2025 Molsentech. All Rights Reserved.
